Stroke is one of the leading causes of death worldwide with limited treatment options [
1]. Platelets play a pivotal role in cerebral ischemia/reperfusion injury by adhering to the damaged vessel wall, leading to further platelet recruitment and thrombus formation. The glycoprotein (GP) Ib-IX-V complex is a crucial platelet receptor for initial tethering and adhesion at sites of vascular injury. This abundant complex on the platelet surface (12,500 copies per cell) consists of the leucine-rich repeat glycoproteins GPIbα, GPIbβ, GPIX and GPV in a 2:2:2:1 ratio [
2]. The adhesive function of GPIb-IX-V is mainly attributed to the interaction of GPIbα with its major ligand von Willebrand factor (VWF), exposed upon vascular damage. The central role of the GPIbα-VWF interaction in mediating initial platelet adhesion is illustrated by the bleeding disorders Bernard Soulier syndrome [
3] and von Willebrand disease [
4], caused by deficiency of GPIb-IX-V or VWF respectively. Besides its interaction with VWF, GPIbα can also engage counter-receptors such as αMβ2 (Mac-1) on neutrophils and P-selectin on activated platelets or endothelial cells [
2]. Other GPIbα ligands include α-thrombin, clotting factors XI and XII, thrombospondin-I and high molecular weight kininogen [
2]. Not surprisingly, the importance of GPIbα far exceeds that of VWF in arterial thrombosis [
5]. Thus, by binding a variety of ligands, GPIbα is a central receptor in different vascular processes of thrombosis and inflammation, all of which may contribute to the progression of ischemic stroke. Here, we studied stroke development in transgenic mice expressing GPIbα in which the extracellular domain was replaced by an isolated domain of the α-subunit of the human IL-4 receptor [
6]. We found that these mice had better stroke outcome, as evidenced by smaller infarct volumes and better functional scores.